logo-loader
viewRedx Pharma Plc

Full interview: Redx Pharma gets green light to increase dose in lead cancer drug trial

Redx Pharma PLC (LON:REDX) CEO Lisa Anson spoke to Proactive London's Andrew Scott following the news they've been given the go-ahead to up the dose of its lead cancer drug.

It comes after the firm successfully navigated the first part of its early-stage trial for RXC004.

The asset's part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. 

Quick facts: Redx Pharma Plc

Price: 7.6 GBX

AIM:REDX
Market: AIM
Market Cap: £9.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

on 19/11/19

RNS

Result of General Meeting

1 hour, 56 minutes ago

Form 8.3 - Redx Pharma plc

5 days, 5 hours ago

Form 8.3 - Redx Pharma PLC

5 days, 22 hours ago

Form 8.3 - Redx Pharma plc

1 week, 4 days ago

Form 8.5 (EPT/RI)

1 week, 5 days ago

2 min read